NEXT BIOTECH

IMC Hits Key Milestones Ahead of Imminent NASDAQ Listing

Next Investors Archived May 17, 2017

Immuron Limited (ASX: IMC) is working in the realm of oral immunotherapies, targeting inflammatory-mediated and infectious diseases and is uniquely positioned to address large unmet needs.

CPH Deliver Australia’s First Medicinal Cannabis Shipment Under New Legislation

Next Investors Archived May 02, 2017

Creso Pharma (ASX: CPH) has made a shipment of medicinal cannabis into Australia – the first import into the country under new government legislation. Under an agreement between CPH and its Australian partner, Health House International Pty Ltd, the pair will distribute a range of cannabis oil products across Australian pharmacies, in compliance with Federal and State legislation.

Beating Cancer via Early Detection: ASX Stock Targeting Multiple Billion Dollar Markets

Next Investors Archived Apr 04, 2017

If you are going to beat cancer, your best bet is to catch it early. Of course, that’s easier said than done. By the time the symptoms of many cancers are apparent, a patient is often already in late stages of the disease. This is particularly true for lung cancer.

ASX Stock to Launch on NASDAQ with Gut Busting Immunotherapy Products

Next Investors Archived Mar 24, 2017

Today’s $30 million capped ASX listed biotech player, which is in the process of listing on the NASDAQ, has thus far flown right under the radar of Australia’s biotech landscape. This scenario is likely to change, however, as this cutting edge company has chosen to take aim at the oral immunotherapy sector, with antibody products […]

Medical Marijuana Stock CPH Plants First Seeds in $800M Brazilian Market

Next Investors Archived Mar 22, 2017

There is no doubt about it – medical marijuana stocks are lighting up the ASX right now, as the mainstream media and investment community at large is finally starting to pick up on what we have been saying for over 12 months now.

Could this ASX Cancer Therapy Junior Attract a Billion Dollar Big Pharma Deal?

Next Investors Archived Mar 16, 2017

One in every two Australians will be diagnosed with cancer by age 85. That’s a staggering statistic that has prompted a great deal of contemplation among doctors, patients and those affected in some way by the consequences of the disease. To try and combat the rise and spread of cancer, Big Pharma, along with smaller biotech companies are working on treatments and potential cures. One $30 million capped ASX junior may have a unique solution.

Aussie Medical Cannabis Market Opens Up: CPH Takes Early Mover Advantage

Next Investors Archived Mar 01, 2017

Creso Pharma (ASX:CPH) is one company set to benefit from the Australian Federal Government’s move this month to improve access to medical cannabis and grant import/export licenses.

Strategic Cannabis Acquisition Complete: MXC Set to Break Ground in Europe, Australia the Next Step

Next Investors Archived Feb 23, 2017

In the case of MGC Pharmaceuticals (ASX: MXC), this ASX-dwelling green thumb is making a bee-line for the global medical cannabis market. This most recent move by the Australian government opens up several commercial channels for MXC with regard to its medical cannabis and cosmetics plays, given recent developments with its European operations.

CDY Backs Hair Raising Growth for 2017 as it Capitalises on US Entry

Next Investors Archived Jan 24, 2017

Volume is a key word for life sciences play Cellmid (ASX: CDY). Its key hair loss product Evolis® aims to replace thinning hair with voluminous locks, while management seeks to volumise revenues, stock liquidity, and ultimately shareholders’ returns.

A Medical Cannabis First: CPH Secures Animal Feed Product Registration

Next Investors Archived Jan 18, 2017

It has been a busy two months for Creso Pharma (ASX: CPH) since we last featured the company in November 2016 and certainly a happy new year thus far with the news that CPH recently obtained the first ever EU registration for two CBD-based animal feed nutraceutical products.

MMJ Set to Unlock Value in Bullish Canadian Cannabis Market

Next Investors Archived Nov 10, 2016

If you hadn’t already heard, cannabis is currently undergoing a breath-taking liberation across the globe as doctors, clinics and government departments all gradually realise its medicinal and commercial endowments.

First Cannabis Revenues in Sight for CPH

Next Investors Archived Nov 07, 2016

The medicinal cannabis industry, whilst attracting a lot of publicity, is still in its early stages as a new niche with very few current or even experienced market participants. Even the big pharma companies have so far been apprehensive towards taking significant stakes in medicinal cannabis, and have preferred to wait out the legislative rigmarole making headlines in the US, Europe and Australia.

NOX Clinic Ready: Phase 1 Study Kicks off in Coming Weeks

Next Investors Archived Oct 26, 2016

Earlier this month, actor and director Ben Stiller publicised the fact he fought (and beat) an aggressive form of prostate cancer in 2014. He states his success over the oft-deadly disease is down to a PSA test that he took at an earlier age than what doctors commonly recommend.

Newly Listed Medical Cannabis Stock Targets $200BN Nutraceutical Opportunity

Next Investors Archived Oct 20, 2016

The low-risk health profile of medical cannabis (MC) has finally gained enough traction to allow legislation to soften… which is why many investors have raised their binoculars on the lookout for bright medical cannabis companies at an early stage of development.

Positive Phase II Results: DXB on Track to Find Kidney Disease Solution

Next Investors Archived Oct 10, 2016

There could be a light at the end of the tunnel for chronic kidney disease sufferers, suffering from a rare form of the disease known as focal segmental glomerulosclerosis (FSGS). In fact several multi-million dollar companies in the space are dedicated to delivering life changing therapies to people living with chronic kidney disease with significant unmet medical needs.

MXC Expecting Imminent Medical Cannabis Revenue Deals

Next Investors Archived Oct 06, 2016

As Australia prepares for the legalisation of medicinal marijuana in November – following bipartisan support at a Federal level and a formal decision by the Therapeutic Goods Administration – the future is looking encouraging for medical cannabis company MGC Pharmaceuticals (ASX:MXC).

CDY Sales Up 72%: $100M Revenue Targets in Place

Next Investors Archived Sep 14, 2016

Calendar year 2016 will go down as a dynamic period of growth in the life of Cellmid (ASX: CDY), a revenue generating life sciences company with lead programs in multiple disease indications and a consumer health business which has just come into its own in the last 12 months.

Canadian Pot Stocks Light Up the TSX: Is MMJ Next?

Next Investors Archived Aug 30, 2016

While MMJ PhytoTech (ASX:MMJ) has operations all around the globe, for its growing operations it has bunkered down in Canada and already established a solid base there. There are several reasons for this: Canada has a more advanced growing industry than anywhere in the world; its TSX listed medical marijuana stocks are gaining traction on the market and regulations are well and truly opening up.

Next Biotech